-0.19 | -5.21%
| Price and Volume | |
|---|---|
| Recent Price | 3.46 |
| 52 Week High | 4.10 |
| 52 Week Low | 1.58 |
| Avg. Daily Vol. (Mil) | 0.90 |
| Beta (3 year) | 1.66 |
| Share Related Items | |
| Mkt Cap (Mil) | 308.41 |
| Shares Out (Mil) | 89.14 |
| Float (Mil) | 53.30 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.30 |
| Current Ratio | 1.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.69 |
| Price/Book | 0.00 |
| Price/Cash Flow | -10.20 |
| Per Share Data | |
| Earnings | -0.62 |
| Sales | 0.94 |
| Book Value | 0.00 |
| Cash Flow | -0.34 |
| Business Summary | |
|---|---|
| Array BioPharma, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. | |
| General Information | |
| 3200 Walnut Street
Boulder, CO 80301 |
|
| www.arraybiopharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 252 | |
| CEO: Ron Squarer | |
| Short Interest | |
| Current Month (Mil) | 3.24 |
| Previous Month (Mil) | 3.35 |
| Short Interest Ratio (Days) | 4.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -31.10 |
| Return on Investments | -307.00 |
| Profitability | |
| Gross Margin | 77.80 |
| EBIT Margin | -29.40 |
| Profit Margin | -44.70 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet